Somebody help why am I following this-! Tarsus Pharmaceuticals, Inc. (TARS) NasdaqGS - NasdaqGS Real Time Price. 19.38+0.73 (+3.91%) As of 10:34AM EDT.
Oh folks I'm on to something!!! there was a recal lof eye drops that sank some bio ACLR maybe... ok thisis tied into that i bet!!! On July 18, 2023, Tarsus Pharmaceuticals (NASDAQ:TARS) received a favorable initiation of coverage from brokerage firm William Blair. With an optimistic outlook, William Blair assigned TARS an Outperform rating and set a price target of $44 per share. The firm’s assessment suggests that TARS is poised to excel in the stock market, potentially reaching the anticipated price target. This announcement was made public on June 29, 2023, as reported on The Wall Street Journal’s UpgradesDowngrades page.
Tarsus started at overweight at William Blair on eyelid inflammation asset Jul. 18, 2023 2:22 PM ET Tarsus Pharmaceuticals, Inc. (TARS) Yikes!
TipRanks Wed, July 19, 2023, 10:13 AM EDT In this article: TARS +3.91% Tarsus Pharmaceuticals (TARS) Now, let’s shift our focus to Tarsus Pharmaceuticals, a clinical stage biotech firm developing therapeutic candidates in the fields of ophthalmology, dermatology, and other areas with substantial unmet medical demands. With small-cap biotech stocks, it’s all about the pipeline catalysts and Tauras has a big one coming up. Its lead candidate is TP-03, indicated to treat Demodex blepharitis, a common eyelid condition that impacts around 25 million Americans. The drug has concluded the clinical testing process and in both its Phase 3 trials hit all primary and secondary endpoints. A PDUFA date has been set for August 25, and if approved, it will be the first FDA-approved treatment and standard of care for the condition. Elsewhere in the pipeline, TP-03 is also being assessed as a treatment for MGD (meibomian gland disease) with a Phase 2a readout anticipated in 2H23. During the second half of the year there should also be a top-line readout from the Phase 2a study of TP-05 in Lyme disease prevention. Additionally, a Phase 2 study of TP-04 as a therapy for Rosacea was initiated in 1Q23. It’s the major catalyst for TP-03 that takes center stage for Oppenheimer analyst Francois Brisebois, although he stresses that the rest of the pipeline is not to be forgotten. “Commercially led by eye care veteran CCO Mottiwala (ex-VP Marketing Allergan Eye Care), TARS is well-positioned to develop a new category, eyelid health. We are particularly encouraged by market research revealing an intent to prescribe for demodex blepharitis (DB) of 93%. As awareness grows, our conviction in TP-03’s market potential is reinforced. Additionally, we believe TP-03 could benefit from key differences between DB and dry eye disease (DED) markets. Finally, although we currently don’t value TARS’ pipeline, we believe it should not be dismissed and see multiple opportunities for growth and monetization,” Brisebois opined. To this end, Brisebois rates TARS shares as Outperform (i.e., Buy) while his price target of $43 implies shares will appreciate by a strong 130% in the months ahead. Brisebois’s take is no anomaly. In fact, all 7 recent analyst reviews are positive, making the consensus view here a Strong Buy. The average target is even more bullish than Brisebois will allow; at $46.43
If anyone knows 5 Below is the concept $5 and below only? People are talking about these guys being a play off Barbie>>>>
favor- Can anyone grab this article that came out yesterday on Seeking Alpha? Stem: Aiming For First Mover Advantage In An Emerging Industry
I sold Phillips PSX finally--- $7,000 gain./ Oil Rises to $80 as Russian Supply Drop Offsets Economy Risks 4 Oil Rises to $80 as Russian Supply Drop Offsets Economy Risks Really confused on oil now--- Summer driving added nothing really, prices are still pretty high at the pump. Travel airline way Up oil should be alot higher. But it's not.
I certainly do not recommend investing this way: But this morning I looked out my kitchen window to the street and parked right below me was a white pickup truck with a cover on the back!!! GBA Buy 1700 WORKSPORT LTD COM NEW (WKSP)I'm in kids....... $3.20 area
Watch this- TELL Tellurian Inc. $1.720.13 (+7.86%)11:31 AM 07/19/23 This is a real fiasco --- a huge LNG port that has run into alot of building out troubles-- they got some financing today we should look into' This is down from $4//